683 results about "Benzothiophene" patented technology

Processes are disclosed for removing sulfur, including cyclic and polycyclic organic sulfur components such as thiophenes and benzothiophenes, from a hydrocarbon feedstock including fuels and fuel components. The feedstock is contacted with a regenerable sorbent material capable of selectively adsorbing the sulfur compounds present in the hydrocarbon feedstock in the absence of a hydrodesulfurization catalyst. In one embodiment, the sorbent can be an active metal oxide sulfur sorbent in combination with a refractory inorganic oxide cracking catalyst support. In another embodiment, the sorbent can be a metal-substituted refractory inorganic oxide cracking catalyst wherein the metal is a metal which is capable in its oxide form, of adsorption of reduced sulfur compounds by conversion of the metal oxide to a metal sulfide. The processes are preferably carried out in a transport bed reactor.

Methods of synthesis of intermediates that are useful as bioisosteres of the indole, benzofuran and benzothiophene scaffold are disclosed.

The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.

Provided are a novel anthracene derivative of a specific structure in which benzofuran or benzothiophene is bonded to anthracene through an arylene group, a material for an organic electroluminescence device and a light emitting material for an organic electroluminescence device each containing the anthracene derivative, and an organic electroluminescence device including an organic thin film layer formed of one or plural layers including at least a light emitting layer, the organic thin film layer being interposed between a cathode and an anode, in which at least one layer of the organic thin film layer contains the anthracene derivative alone or as a component of a mixture. The organic electroluminescence device has high luminous efficiency and is capable of emitting light with a long lifetime, and the device can be realized by the anthracene derivative.

A proton pump inhibitor containing a compound represented by the formula (I)wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile. Also provided are methods for preparing iminobenzo[b]thiophene and benzo[b]thiophenone compounds.

A compound of formula (I):or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of the activity of the estrogen receptor, including degrading the estrogen receptor, the treatment of diseases and conditions mediated by the estrogen receptor,

This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range.The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.

The present invention is directed to benzothiophene compositions, preferably nanoparticulate raloxifene hydrochloride compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the raloxifene hydrochloride nanoparticulate composition have an effective average particle size of less than about 2000 nm.

The invention discloses a polymerizable compound represented in a formula I, liquid crystal composition containing the polymerizable compound represented in the formula I as well as a liquid crystal display device. In the formula I, X1-X7 represent H, F or CH3 independently, and Y1 and Y2 represent CH3, CH2F, CHF2 or CF3 independently. The polymerizable compound is particularly suitable for PSVA liquid crystal composition applied to a display or TV, and has no or obviously reduced image sticking after long-term operation.

The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and / or prevention and / or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

A method of desulfurizing / refining a hydrocarbon oil by which sulfur compounds are diminished to an extremely low concentration at a relatively low equipment cost and operating cost. The method of desulfurizing / refining a hydrocarbon oil comprises bringing a hydrocarbon oil containing at least one sulfur compound selected from the group consisting of thiophene compounds, benzothiophene compounds, and dibenzothiophene compounds and optionally further containing aromatic hydrocarbons into contact with a solid acid catalyst and / or an activated carbon having a transition metal oxide supported thereon to thereby desulfurize the oil. The solid acid catalyst preferably is a solid ultrastrong-acid catalyst selected among sulfuric acid radical / zirconia, sulfuric acid radical / alumina, sulfuric acid radical / tin oxide, sulfuric acid radical / iron oxide, tungstic acid / zirconia, and tungstic acid / tin oxide.

A method of desulfurizing / refining a hydrocarbon oil by which sulfur compounds are diminished to an extremely low concentration at a relatively low equipment cost and operating cost. The method of desulfurizing / refining a hydrocarbon oil comprises bringing a hydrocarbon oil containing at least one sulfur compound selected from the group consisting of thiophene compounds, benzothiophene compounds, and dibenzothiophene compounds and optionally further containing aromatic hydrocarbons into contact with a solid acid catalyst and / or an activated carbon having a transition metal oxide supported thereon to thereby desulfurize the oil. The solid acid catalyst preferably is a solid ultrastrong-acid catalyst selected among sulfuric acid radical / zirconia, sulfuric acid radical / alumina, sulfuric acid radical / tin oxide, sulfuric acid radical / iron oxide, tungstic acid / zirconia, and tungstic acid / tin oxide.

There is provided a 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivative which is useful in the treatment of respiratory syncytial virus (RSV) infection and for the prevention of disease associated with RSV infection. (Formula (1)).

Processes are disclosed for removing sulfur, including cyclic and polycyclic organic sulfur components such as thiophenes and benzothiophenes, from a hydrocarbon feedstock including fuels and fuel components. The feedstock is contacted with a regenerable sorbent material capable of selectively adsorbing the sulfur compounds present in the hydrocarbon feedstock in the absence of a hydrodesulfurization catalyst. In one embodiment, the sorbent can be an active metal oxide sulfur sorbent in combination with a refractory inorganic oxide cracking catalyst support. In another embodiment, the sorbent can be a metal-substituted refractory inorganic oxide cracking catalyst wherein the metal is a metal which is capable in its oxide form, of adsorption of reduced sulfur compounds by conversion of the metal oxide to a metal sulfide. The processes are preferably carried out in a transport bed reactor.

The invention discloses mesoporous ZSM-5 zeolite, a mesoporous ZSM-5 zeolite-loaded metal sulfide catalyst and an application. The synthesizing method of the mesoporous ZSM-5 zeolite comprises the following steps: (1) after uniformly mixing diallylamine and concentrated hydrochloric acid, adding dimethyl diallyl ammonium chloride, uniformly stirring and reacting for 1-6 hours at 60-120 DEG C, and cooling to obtain a template agent DMMC (Dimethylol Methyl Carbamate); (2) preparing acidified aluminum sulfate liquor by aluminum sulfate, concentrated sulfuric acid and water; (3) adding water into water glass, uniformly stirring, adding NaOH, adding the template agent DMMC after cooling to room temperature, continuously stirring for 2-5 hours, then adding the acidified aluminum sulfate liquor under stirring, and stirring for 2-8 hours to obtain a gel in a final state; (4) crystallizing the gel in the final state obtained in the step (3), filtering, drying and calcining to obtain the mesoporous ZSM-5 zeolite. The mesoporous ZSM-5 zeolite-loaded metal sulfide catalyst prepared by taking the mesoporous ZSM-5 zeolite as a carrier is applied to hydrodesulfurization of 4, 6-dimethyl dibenzothiophene and hydrocracking reaction of n-decane, thereby greatly improving the raw material conversion ratio.

The invention relates to a fluorescent compound and application thereof in detecting trace methylamphetamine, which is characterized in that the structural general formula of the fluorescent compound is shown in the specification, wherein R1 and R2 in the formula are respectively one fluorescent substituent group and the derivative thereof, the fluorescent substituent group comprises triphenylamine, benzene, naphthalene, anthracene, pyrene, fluorine, dinaphthalene, carbazole, benzothiophene, phenothiazinyl and rhodamine, and R3 is alkyl substituent. The steam action of the fluorescent compound provided by the invention and the methylamphetamine can carry out obvious fluorescent quenching in short time, and the methylamphetamine can be detected according to the fluorescent intensity quenching. The fluorescent compound is a novel fluorescent sensing material for detecting methylamphetamine. The detection limit reaches 100 ppb.

Disclosed is an agent comprising a benzothiophene alkyl ether derivative represented by the general formula below or a salt thereof:wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl group, an arylsulfonyl group, a carbamoyl group, a heterocyclic group, an amino group, a hydroxyl group, a carboxyl group, a nitro group, an oxo group and the like; R3 represents an alkylamino group which may be substituted or an amino or hydroxyl group which may be protected; and m and n independently represent an integer ranging from 1 to 6. The agent is useful as a neurogenesis inducer or a therapeutic agent for neuropathy.

A method of controlling Take-All disease of plants by applying a fungicide of the formula wherein Z1 and Z2 are C and are part of an aromatic ring which is [benzothiophene]thiophene; and A is [selected from] -C(X)-amine [wherein the amine is an unsubstituted, monosubstituted or disubstituted amino radical]wherein the amine is a monosubstituted or a disubstituted amine, wherein one of the substituents has a cyclic moiety, said cyclic moiety which is chosen from the group consisting of thienyl, furanyl, and a non-heterocyclic substituent, wherein when the amine is disubstituted, the second substituent is a non-cyclic substituent, -C(O)-SR3, -NH-C(X)R4, [and] or -C(=NR3)-XR7; B is -Wm-Q(R2)3 or selected from [O-tolyl]o-tolyl, 1-naphthyl, 2-naphthyl, and 9-phenanthryl, each optionally substituted with halogen or R4; Q is C, Si, Ge, or Sn; W is -C(R3)pH(2-p)-; or when Q is C, W is selected from [-C(R3)pH(2-p),[-C(R3)pH(2-p)-, -N(R3)mH(1-m)-, [-S(O)p-,] -S(O)p-, and -O-, X is [0] O or S; n is [0, 1, 2, or 3]2; m is 0 or 1; p is 0, 1, or 2; wherein the two R groups are combined with the thiophene ring to form a fused ring which is benzothiophene; each R and R2 is independently defined herein; R3 is C1-C4 alkyl; R4 is C1-C4 alkyl, haloalkyl, alkoxy, alkylthio, alkylamino, or dialkylamino; and R7 is C1-C4 alkyl, haloalkyl, or phenyl, optionally substituted with halo, nitro, or R4; or an agronomic salt thereof.

A process for producing gasoline having reduced sulfur content while maintaining or improving octane rating is provided. A gasoline fraction having a substantial amount of olefinic and sulfur compounds produced from fluidized catalytic cracking or coking is contacted first with an adsorbent to selectively remove alkylated thiophenic, benzothiophene, and alkylated benzothiophenic sulfur compounds. The adsorptively treated gasoline fraction is then introduced into a conventional hydrodesulphurizing catalyst bed with hydrogen for further removal of sulfur compounds. Adsorbent containing alkylated thiophenic, benzothiophene, and alkylated benzothiophenic compounds are regenerated through washing with a hydrocarbon solvent and subsequent drying-out by warming.

Compounds having activity as inhibitors of Gl2C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of Gl2C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

The invention provides a novel preparation method of brexpiprazole, belonging to the technical field of medicines and chemical synthesis, and solving the problems of more impurities, low yield and serious pollution of existing brexpiprazole preparation methods. According to the method, 4-hydroxy benzothiophene is taken as a starting material, an intermediate V is obtained by four steps of reactions, an intermediate VII is obtained from 7-hydroxy-2-quinolone by two steps of reactions, and the intermediate V and the intermediate VII are subjected to condensation to obtain the brexpiprazole meeting clinic medicinal requirements. The preparation method is easy for getting raw materials, low in price, simple in operation, and mild in reaction condition, and has good industrialized application values.

The invention relates to a novel benzothiophene derivative and application thereof in preventive and / or treatment medicine for breast cancer and osteoporosis. The benzothiophene derivative is an ideal selective estrogen receptor modulator, can be used for treating or preventing various indications related to estrogen functions, and is particularly applicable to treating post-menopause breast cancer and osteoporosis. The compound has the advantages that oxidative metabolism is lowered, effective bioavailability is higher, and accordingly, dosage of the compound is little, tolerance of the compound is fine, and side effects are low.

A process for producing gasoline having reduced sulfur content while maintaining or improving octane rating is provided. A gasoline fraction having a substantial amount of olefinic and sulfur compounds produced from fluidized catalytic cracking or coking is contacted first with an adsorbent to selectively remove alkylated thiophenic, benzothiophene, and alkylated benzothiophenic sulfur compounds. The adsorptively treated gasoline fraction is then introduced into a conventional hydrodesulphurizing catalyst bed with hydrogen for further removal of sulfur compounds. Adsorbent containing alkylated thiophenic, benzothiophene, and alkylated benzothiophenic compounds are regenerated through washing with a hydrocarbon solvent and subsequent drying-out by warming.

The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

A [1]benzothieno[3,2-b][1]benzothiophene compound expressed by General Formula (I): General Formula (I) where X and Y are each independently a hydrogen atom; a halogen atom; or a functional group having a straight or branched aliphatic alkyl group optionally having a halogen atom, a functional group having an alicyclic alkyl group optionally having a halogen atom, a functional group having a straight or branched aliphatic alkenyl group optionally having a halogen atom, a functional group having an alicyclic alkenyl group optionally having a halogen atom, a functional group having a carboxyl group, or a functional group having a thiol group, as a partial structure; and X and Y are the same or each independently different, provided that at least one of X and Y has a straight or branched aliphatic alkenyl group, an alicyclic alkenyl group, a carboxyl group or a thiol group, as a partial structure.